Human papillomavirus DNA detection in ThinPrep Pap test vials is independent of cytologic sampling of the transformation zone

Gynecologic Oncology

Volumn 107, Issue 2, 2007, Pages 231-235

  Zhao, Chengquan ^a   Austin, R Marshall ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Human papillomavirus; Hybrid capture 2 test; ThinPrep Pap test; Transformation zone

Indexed keywords

VIRUS DNA;

ARTICLE; CANCER SCREENING; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; PAPANICOLAOU TEST; PRIORITY JOURNAL; RISK ASSESSMENT; UTERINE CERVIX CYTOLOGY; UTERINE ENDOCERVIX; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS;

ADOLESCENT; ADULT; AGED; CELL TRANSFORMATION, NEOPLASTIC; CERVIX UTERI; CHILD; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL DYSPLASIA; VAGINAL SMEARS;

EID: 35348912775     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.06.025     Document Type: Article

References (57)

1. George S., Abrahams Y., Karim S.Z., and Kothari A. Improving the quality of cervical screening. Int J Obstet Gynaecol 111 (2004) 960-966
2. Raab S.S., Andrew-Jaja C., Condel J.L., and Dabbs D.J. Improving Papanicolaou test quality and reducing medical errors by using toyota production system methods. Am J Obstet Gynecol Jan 194 1 (2006) 57-64
3. Alons-van Kordelaar J.J.M., and Boon M.E. Diagnostic accuracy of squamous cervical lesions studied in spatula-cytobrush smears. Acta Cytol 32 (1988) 801-804
4. Boon M.E., Alons-van Kordelaar J.J.M., and Rietveld-Scheffers P.E.M. Consequences of the introduction of combined spatula and cytobrush sampling for cervical cytology: improvements in smear quality and detection rates. Acta Cytol 30 (1986) 264-270
5. Boon M.E., deGraaff Guilloud J.C., and Rietveld W.J. Analysis of five sampling methods for the preparation of cervical smears. Acta Cytol 33 (1989) 843-848
6. Elias A., Linthorst G., Bekker B., et al. The significance of endocervical cells in the diagnosis of cervical epithelial changes. Acta Cytol 27 (1983) 225-229
7. Frost J.K. Diagnostic accuracy of "cervical smears". Obstet Gynecol Surv 24 (1969) 893-908
8. Killough B.V., Clark A.H., and Garvin J. Correlation between cytodiagnosis and the presence of endocervical or squamous metaplastic cells in gynecologic smears (abstract). Acta Cytol 32 (1988) 758
9. Mauney M., Eide D., and Sotham J. Rates of condyloma and dysplasia in Papanicolaou smears with and without endocervical cells. Diagn Cytopathol 6 (1990) 18-21
10. Mintzer M., Curtis P., Redneck J.C., et al. The effect of the quality of Papanicolaou smears on the detection of cytologic abnormalities. Cancer (Cancer Cytopathol) 87 (1999) 113-117
11. Mitchell H., and Medley G. Influence of endocervical status on the cytologic prediction of cervical intraepithelial neoplasia. Acta Cytol 36 (1992) 875-880
12. (NCI) National Cancer Institute. The Bethesda system for reporting cervical/vaginal cytologic diagnoses. Acta Cytol 37 (1993) 115-124
13. (NCI) National Cancer Institute. The Bethesda system for reporting cervical/vaginal cytologic diagnoses. Diagn Cytopathol 9 (1993) 235-243
14. Richart R.M., and Vaillant H.W. Influence of cell collection techniques upon cytological diagnosis. Cancer 18 (1965) 1474-1478
15. Robertson J.H., and Woodend B. Negative cytology preceding cervical cancer: causes and prevention. J Clin Pathol 46 (1993) 700-702
16. Vooijs G.P., Elias A., van der Graaf Y., et al. Relationship between the diagnosis of epithelial abnormalities and the composition of cervical smears. Acta Cytol 29 (1985) 323-328
17. Wied G.L. Importance of the site from which vaginal cytologic smears are taken. Am J Clin Pathol 25 (1955) 742-750
18. Woodman C.B., Yates M., Ward K., et al. Indicators of effective cytological sampling of the uterine cervix. Lancet ii (1989) 88-90
19. Baer A., Kiviat N.B., Kulasingam S., et al. Liquid-based Papanicolaou smears without a transformation zone component: should clinicians worry?. Obstet Gynecol 99 (2002) 1053-1059
20. Beilby J.O.W., Bourne R., Guillebaud J., et al. Paired cervical smears: a method of reducing the false-negative rate in population screening. Obstet Gynecol 60 (1982) 46-48
21. Hislop T.G., Band P.R., Deschamps M., et al. Cervical cancer screening in Canadian native women: adequacy of the Papanicolaou smear. Acta Cytol 38 (1994) 29-32
22. Kivlahan C., and Ingram E. Papanicolaou smears without endocervical cells: are they inadequate?. Acta Cytol 30 (1986) 258-260
23. Selvaggi S.M., and Guidos B.J. Endocervical component: is it a determinant of specimen adequacy?. Diagn Cytopathol 26 (2002) 53-55
24. Szarewski A., Cuzick J., Nayagam M., et al. A comparison of four cytological sampling techniques in a genitourinary medicine clinic. Genitourin Med 66 (1990) 439-443
25. Szarewski A., Curran G., Edwards R., et al. Comparison of four cytologic sampling techniques in a large family planning center. Acta Cytol 37 (1993) 457-460
26. Bos A.B., van Ballegooijen M., Elske van den Akker-van Marle M., et al. Endocervical status is not predictive of the incidence of cervical cancer in the years after negative smears. Am J Clin Pathol 115 (2001) 851-855
27. Siebers A.G., de Leeuw H., Verbeek A.L.M., et al. Prevalence of squamous abnormalities in women with a recent smear without endocervical cells is lower as compared to women with smears with endocervical cells. Cytopathology 14 (2003) 58-65
28. Vooijs G.P., Elias A., van der Graaf Y., et al. Relationship between the diagnosis of epithelial abnormalities and the composition of cervical smears. Acta Cytol 29 (1985) 323-328
29. Mitchell H., and Medley G. Longitudinal study of women with negative cervical smears according to endocervical status. Lancet 337 (1991) 265-267
30. Mitchell H. Longitudinal analysis of histologic high-grade disease after negative cervical cytology according to endocervical status. Cancer (Cancer Cytopathol) 93 (2001) 237-240
31. (NCI) National Cancer Institute. The Bethesda system for reporting cervical/vaginal cytologic diagnoses. Acta Cytol 37 (1993) 115-124
32. Vooijs G.P., Elias A., van der Graaf Y., et al. Relationship between the diagnosis of epithelial abnormalities and the composition of cervical smears. Acta Cytol 29 (1985) 323-338
33. Absence of endocervical cells on a Pap test. ACOG Committee Opinion Bulletin vol. 153 (1995), American College of Obstetricians and Gynecologists
34. Davey D.D., Austin R.M., Birdsong G., Buck H.W., Cox J.T., Darragh T.M., et al. ASCCP patient management guidelines: Pap test specimen adequacy and quality indicators. Am Soc Colposcopy Cervical Path J Lower Genital Tract Dis 6 3 (2002) 195-199
35. Sherman M.E., Lorincz A.T., Scott D.R., et al. Baseline cytology. Human papillomavirus testing and risk for cervical neoplasia: a 10 year cohort analysis. J Natl Cancer Inst 95 (2003) 46-52
36. Castle P.E., Wacholder S., Lorincz A.T., et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst 94 (2002) 1406-1414
37. Castle P.E., Wacholder S., Sherman M.E., et al. Absolute risk of subsequent abnormal Pap among oncogenic human papillomavirus DNA-positive cytologically negative women. Cancer 95 (2002) 2145-2155
38. Khan M.J., Castle P.E., Lorincz A.T., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97 (2005) 1072-1079
39. Dzura B., Quinn S., and Richard K. Performance of an imaging system vs. manual screening in the detection of squamous intraepithelial lesions of the cervix. Acta Cytol 50 (2006) 309-311
40. Castle P.E., Lorincz A.T., Scott D.R., Sherman M.E., Glass A.G., Rush B.B., et al. Comparison between prototype Hybrid Capture 3 and Hybrid Capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer. J Clin Microbiol 42 9 (Sept 2003) 4022-4030
41. Navina S., Savik K., Miller L., McKeon D., Wang X., Gulbahce E., et al. The effect of the presence of an adequate endocervical/transformation zone (TZC) component on the detection of high risk HPV (hr-HPV) DNA. A study of 7990 cases classified by the 2001 Bethesda system. Cancer Cytopathol 1085 (2006) 397
42. Digene Hybrid Capture®2 (HC2) High-risk HPV DNA test-P890064/S009. http://www.fda.gov/cdrh/pdf/p890064s009.html.
43. Klipp J. Competitive market analysis for laboratory management decision makers. Lab Econ 1 9 (2006) 1-7
44. Burk R.D., Kelly P., Feldman J., Bromberg J., Vermund S.H., DeHovitz J.A., et al. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Transm Dis 23 4 (Jul-Aug 1996) 333-341
45. Alonso I., Torne A., Puig-Tintore L.M., Esteve R., Quinto L., Campo E., et al. Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3. Gynecol Oncol Nov 103 2 (2006) 631-636 [Electronic publication 2006 Jun 14]
46. Kreimer A.R., Guido R.S., Solomon D., Schiffman M., Wacholder S., Jeronimo J., et al. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomark Prev May 15 5 (2006) 908-914
47. Zielinski G.D., Bais A.G., Helmerhorst R.J., Verheijen R.H., deSchipper F.A., Snijders P.J., et al. HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv Jul 59 7 (2004) 543-553
48. Howlett R.I., Marrett L.D., Innes M.K., Rosen B.P., and McLachlin C.M. Decreasing incidence of cervical adenocarcinoma in Ontario: is this related to improved endocervical Pap test sampling?. Int J Cancer 120 (2006) 362-367
49. Tacken M.A.J.B., Braspenning J.C.C., Mulder J., Hermens R.P.M.G., Nelen W.L.D.M., de Bakker D.H., et al. Loss to follow-up of cervical smears without endocervical cells is not disturbing. Eur J Gynaecol Oncol 27 (2006) 42-46
50. Derchain S.F., Rabelo-Santos S.H., Sarian L.O., Zeferino L.C., de Oliveira Zambeli E.R., do Amaral Westin M.C., et al. Human papillomavirus DNA detection and histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in their Pap smears. Gynecol Oncol Dec 95 3 (2004) 618-623
51. Andersson S., Rylander E., Larsson B., Strand A., Silfversvard C., and Wilander E. The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer 37 (2001) 246-250
52. Castellsague X., Diaz M., deSanjose S., Munoz N., Herrero R., Franceschi S., et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 98 5 (Mar 2006) 303-315
53. Bertrand M., Lickrish G.M., and Colgan T.J. The anatomic distribution of cervical adenocarcinoma in situ: implications for treatment. Am J Obstet Gynecol Jul 157 1 (1987) 21-25
54. Kitchener H.C., Almonte M., Wheeler P., Desai M., Gilham C., Bailey A., et al. HPV testing in routine cervical screening: cross sectional data from the artistic trial. Br J Cancer 95 (2006) 56-61
55. Pirog E.C., Kleter B., Olgae S., Bobkiewicz P., Lindeman J., Quint W.G., et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol 157 (2000) 1055-1062
56. Wright T.C., Schiffman M., Solomon D., Cox J.T., Garcia F., Goldie S., et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Am. Coll. Obstet. Gynecol (Current Commentary) Feb 103 2 (2004) 304
57. Austin R.M. Human papilloma virus reporting. Minimizing patient and laboratory risk. Arch Pathol Lab Med 127 (2003) 973-977